Ampliphi Biosciences Corp Share Price Nyse
Equities
APHB
US03211P2020
Biotechnology & Medical Research
Sales 2024 * | 45.38L 38Cr | Sales 2025 * | 27.5L 23Cr | Capitalization | 10Cr 839.59Cr |
---|---|---|---|---|---|
Net income 2024 * | -7.2Cr -601.44Cr | Net income 2025 * | -6.7Cr -559.67Cr | EV / Sales 2024 * | 22.1 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 36.5 x |
P/E ratio 2024 * |
-1.46
x | P/E ratio 2025 * |
-2.14
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 29.72% |
Managers | Title | Age | Since |
---|---|---|---|
Deborah Birx
CEO | Chief Executive Officer | 68 | 11/23/11 |
Richard Rychlik
DFI | Director of Finance/CFO | 68 | 05/23/05 |
Mina Pastagia
CTO | Chief Tech/Sci/R&D Officer | - | 26/20/26 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 64 | 12/20/12 | |
Joseph Patti
BRD | Director/Board Member | 60 | 09/19/09 |
Jules Haimovitz
BRD | Director/Board Member | 73 | 01/21/01 |
1st Jan change | Capi. | |
---|---|---|
+31.67% | 5.27TCr | |
+38.00% | 3.9TCr | |
-9.36% | 3.85TCr | |
+25.88% | 3.04TCr | |
-11.17% | 2.64TCr | |
+10.81% | 2.61TCr | |
+44.98% | 1.42TCr | |
+33.26% | 1.26TCr | |
-5.42% | 1.15TCr |